Key facts
- This page summarizes Sandra Leung's Form 4 filing for Bausch Health Companies Inc. (BHC).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jul 2026, 16:10.
Sandra Leung - 30 Jun 2026 Form 4 Insider Report for Bausch Health Companies Inc. (BHC)
- Reporting relationship
- Director
- Issuer ticker
- BHC
- Reported as of
- 30 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2026, 16:10:20 UTC
- Prior SEC filing
- 26 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brianna M. Dorsi, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sandra Leung filed Form 4 for Bausch Health Companies Inc. (BHC) on 02 Jul 2026.
Change
- Previous filing in this sequence was filed on 26 May 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001199294
Primary reporting owner
LEUNG SANDRA
- Relationship
- Director
- Address
- 400 SOMERSET CORPORATE BLVD., BRIDGEWATER
- Signature
- /s/ Brianna M. Dorsi, attorney-in-fact
- Signature date
- 02 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BHC
transaction
Common Shares, No Par Value
Award
- Transaction value
- Shares
- +6,845
- Change %
- +7.6%
- Price
- $4.93*
- Shares after
- 97,070
- Date
- 30 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Reflects Restricted Share Units issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending June 30, 2026, each representing a contingent right to receive one common share, no par value, of the Issuer.